Business
Accuray develops, manufactures, sells, and supports radiation therapy systems, including CyberKnife and TomoTherapy platforms.
Accuray revenue rose 2.7%, net loss narrowed to $1.6M, and free cash flow improved but stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Radiation therapy systemsNote
- Revenue — Revenue rose 2.7% to $458.5MOK
- Profitability — Net loss narrowed to $1.6MOK
- Cash — FCF improved to negative $1.4MNote
- Balance sheet — Debt down; equity up 80.0%OK
- Insiders — 4 buys / 0 sellsOK
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2026, as ACCURAY INC reports it. History and quarterly detail are in the app.
- Service$229.2M
- Product$172.7M
Leadership changes
From ACCURAY INC's own filings, the day they're filed.
- Anne LeGrand · Directors · departureeff. 2026-07-29
- Leonel Peralta · Chief Operations Officer · departureeff. 2026-04-26
- Accuray Incorporated · Directors · departureeff. 2026-04-26
Latest filings
- 10-K · Annual report2026-08-27
- DEF 14A · Annual proxy (pay & governance)2026-08-24
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ACCURAY INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.